email: info@ranir.ru
Рус | Eng

Поиск по сайту

Антиретровирусная терапия во время беременности. Окончание

Ссылки на источники

1. Connor EM et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 331: 1173-1180, 1994.

2. Wade NA et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 339: 20, 1409, 1998.

3. Mofenson L et al. Risk factors for perinatal transmission of HIV type 1 in women treated with zidovudine. N Engl J Med 341: 385-393, 1999.

.

4. Lindgren ML et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA 282: 531, 1999.

5. Chotpitayasunondh T et al. Impact of short-course zidovudine regimen on transmission risk and risk factors for perinatal HIV transmission, Bangkok, Thailand. 14th International AIDS Conference, Barcelona, abstract WePeB5928, 2002.

6. Shaffer D et al. Combination prophylaxis for prevention of maternal-infant HIV transmission (editorial). Lancet 353: 773-780, 1999.

7. Chuachoowong R et al. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission. J Infect Dis 181: 99-106, 2000.

8. Lallemont M et al. Single-dose perinatal nevirapine plus standard zidouvdine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 343: 982-991, 2000.

9. Chaisilwattana P et al. Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand. Clin Infect Dis 35: 1405-1413, 2002.

10. Mandelbrot L et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1, JAMA 285: 2083-2093, 2001.

11. Gray G et al. Preliminary efficacy, safety, tolerability and pharmacokinetics of short course regimens of nucleoside analogues for the prevention of mother-to-child transmission (MTCT) of HIV. 13th International AIDS Conference, Durban, abstract TuOrB355, 2000.

12. Guay LA et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354: 795-802, 1999.

13. Jackson JB et al. A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 in uninfected subjects at high risk. AIDS 17: 547-553, 2003.

14. Moodley D et al. Evaulation of safety and efficacy of two simple regimens for the prevention of mother to child transmission (MTCT) in HIV infection: nevirapine vs lamivudine and zidovudine used in a randomised clinical trial (the SAINT study). 13th International AIDS Conference, Durban, abstract TuOrB356, 2000.

15. Kagaayi J et al. Maternal self-medication and provision to newborns by women in Rakai, Uganda. J Acquir Immune Defic Syndr 39: 121-124, 2005.

16. Lallemant M et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 351: 217-228, 2004.

17. Gray GE et al. A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers. AIDS 19: 1289-1297, 2005.

18. Chi BH et al. Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024. AIDS 19: 1857-1864, 2005.

19. Cressey T et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 38: 283-288, 2005.

20. Muro E et al. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine. Implications for intervention studies. J Acquir Immune Defic Syndr 39: 419-421, 2005.

21. McIntryre JA et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 6(10):e1000172. Epub Oct 27, 2009.

22. Gray G et al. NNRTI-resistant mutations in HIV-1 infected infants following single dose nevirapine (Sd-NVP) are reduced by the addition of short course zidovudine and 3TC. Third International AIDS Society Conference on HIV Pathogenesis and Treatment, abstract TuPe5.4P01, 2005.

23. McIntryre JA et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 6(10):e1000172. Epub Oct 27, 2009.

24. ANRS 1201/1202 DITRAME PLUS Study Group. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 19: 309-318, 2005.

25. Shapiro R et al. Maternal single-dose nevirapine may not be needed to reduce mother to child transmission in the setting of maternal and infant zidovudine and infant single-dose nevirapine: results of a randomized clinical trial in Botswana. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 74LB, 2005.

26. Taha TE et al. Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial. Lancet 362: 1171-1177, 2003.

27. Colgrove RC et al. Zidovudine resistance after vertical transmission of HIV-1. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 265, 1999.

28. Kully C et al. Codon 215 mutations in human immunodeficiency virus-infected pregnant women. J Infect Dis 179: 705-708, 1999.

29. Palumbo P et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis 184: 1120-1126, 2001.

30. Masquelier B et al. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort. J Acquir Immune Defic Syndr 27: 99-104, 2001.

31. Welles SL et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group, 2000.

32. Labarlestier et al. Drug resistance is uncommon in pregnant women with low viral loads taking zidovudine monotherapy to prevent perinatal HIV transmission. AIDS 17: 2665-2667, 2003.

33. Ekpini RA et al. Changes in plasma HIV-1-RNA viral load and CD4 cell counts, and lack of zidovudine resistance among pregnant women receiving short-course zidovudine. AIDS 16: 625-630, 2002.

34. Coffie P et al. Short-course zidovudine and lamivudine or single-dose nevirapine-containing PMTCT compromises 12-month response to HAART in African Women, Abidjan, Côte d’Ivoire (2003-2006). Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, abstract 93LB, 2007.

35. Coffie P et al. Short-course zidovudine and lamivudine or single-dose nevirapine-containing PMTCT compromises 12-month response to HAART in African Women, Abidjan, Côte d’Ivoire (2003-2006). Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, abstract 93LB, 2007.

36. Mandelbrot L et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 285: 2083-2093, 2001.

37. Clarke JR et al. Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy. J Med Virol 59: 364-368, 1999.

38. Chokephaibulkit K et al. Lack of resistant mutation development after receiving short-course zidovudine plus lamivudine to prevent mother-to-child transmission. AIDS 19: 1231-1233, 2005.

39. Lockman S et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356 (2): 135-147, 2007.

40. Chi BH et al. Maternal immune response and clinical outcomes on NNRTI-based antiretroviral therapy (ART) following exposure to single-dose nevirapine (NVP) for prevention of mother-to-child transmission. Sixteenth International AIDS Conference, Toronto, Canada, abstract WeAb0104, 2006.

41. Lallemant M et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 351: 217-228, 2004.

42. Jourdain G et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 351: 229-240, 2004.

43. Coovadia A et al. Virologic response to NNRTI treatment among women who took single-dose nevirapine 18 to 36 months earlier. Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, abstract 641, 2006.

44. Flys TS et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission. J Infect Dis 195 (5): 711-5, 2007.

45. Eure C et al. Effectiveness of repeat single-dose nevirapine in subsequent pregnancies among Ugandan women. Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, abstract 125, 2006.

46. Martinson N et al. Effectiveness of single-dose nevirapine in consecutive pregnancies in Soweto and Abidjan. Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, abstract 722, 2006.

47. Cooper ER et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29 (5): 484-494, 2002.

48. Bucceri AM et al. Combination antiretroviral therapy in 100 HIV-1-infected pregnant women. Hum Reprod 17: 436-441, 2002.

49. Leyes M et al. Prevention of vertical transmission of HIV-1 in Mallorca, Spain. Impact of antiretroviral therapy from 1995 to 2000, 2002.

50. Solis I et al. Experience on antiretroviral therapy during pregnancy: results from a large multicenter study. Fourteenth International AIDS Conference, Barcelona, abstract WePeB5961, 2002.

51. Palombi L et al. HAART in pregnancy: safety, effectiveness and protection from viral resistance: results from the DREAM cohort. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 67, 2005.

52. Towne-Gold B et al. Highly active antiretroviral therapy for the prevention of perinatal HIV transmission in Africa: Mother-to-child HIV Transmission Plus, Abidjan, Cote d'Ivoire, 2003-2004. Twelfth Conference on Retroviruses and Opportunistic Infections, abstract 785, 2005.

53. Cunningham CK et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 186: 181-188, 2002.

54. Lyons F et al. Management of sequential pregnancies in HIV-infected women. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 786, 2005.

55. McDonald C et al. Why are children still being infected with HIV? Experiences in prevention in mother-to-child transmission of HIV in a complex south London university hospital population. Twelfth Annual Conference of the British HIV Association, Brighton, abstract 04, 2006.

56. Watts DH et al. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 443: 299-305, 2007.

57. Feiturna-Sperling C et al. Hematologic effects of maternal antiretroviral therapy and transmission prophylaxis in HIV-1- exposed uninfected newborn infants. J Acquir Immune Defic Syndr 45: 43-51, 2007.

58. Walker DM et al. Transplacental carcinogenicity of 3’-Azido-3’Deoxythymidine in B6C3F1 mice and F344 rats. Environmental and Molecular Mutagenesis 48:283-298, 2007.

59. Hong H-H L. Genetic alterations in K-ras and p53 cancer genes in lung neoplasms from Swiss (Cd-1) male mice exposed transplacentally to AZT. Environmental and Molecular Mutagenesis 48: 299-306, 2007.

60. Escobar PA et al. Genotoxicity assessed by the Comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC. Environmental and Molecular Mutagenesis 48: 330-343, 2007.

61. Alimenti A et al. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. Pediatrics 118 (4): 1139-45, 2006.

62. Lorenzi P et al. Anti-retroviral therapies during pregnancy: maternal, fetal and neonatal effects. AIDS 12: F241-F247, 1998.

63. Taha TE et al. Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. AIDS 16: 851-858, 2002.

64. Shiramizu B et al. Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract P771, 2003.

65. Poirier MC et al. Long-term mitochondrial toxicity in HIV-uninfected infants born to HIV-infected mothers. J Acquir Immune Defic Syndr 33: 175-183, 2003.

66. Barrett B et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. Persistent mitochondrial AIDS 17: 1769-1785, 2003.

67. Chotpitayasunondh T et al. Safety of late in utero exposure to zidovudine in infants born to human immunodeficiency virus-infected mothers: Bangkok. Bangkok Collaborative Perinatal HIV Transmission Study Group. Pediatrics 107: E5, 2001.

68. Lipshultz SE et al. Absence of cardiac toxicity of zidovudine in infants. N Engl J Med 343: 759-766, 2000.

69. Puga AM et al. Abacavir use in HIV-positive pregnant women. Fourteenth International AIDS Conference, Barcelona, abstract WePeB5909, 2002.

70. Justman JE et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. AIDS 32: 298-302, 2003.

71. Stek A et al. Reduced lopinavir exposure during pregnancy: preliminary pharmacokinetic results from PACTG 1026. Fifteenth International AIDS Conference, Bangkok, 2004.

72. Timmermans S et al. Nelfinavir and nevirapine side-effects during pregnancy. AIDS 19: 795-799, 2005.

73. Suy A et al. Increased risk of pre-eclampsia and foetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy. Fifteenth International AIDS Conference, Bangkok, abstract ThOrB1359, 2004.

74. Wimalasundera RC et al. Pre-eclampsia, antiretroviral therapy, and immune reconstitution. 2002.

75. Marzolini C et al. Transplacental passage of protease inhibitors at delivery. AIDS 16: 889-893, 2002.

76. Mirochnick M et al. Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. J Acquir Immune Defic Syndr 39: 189-194, 2005.

77. Acosta EP et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 48: 430-436, 2004.

78. Zorrilla CD et al. Clinical response, safety, and tolerabiliy to saquinavir-SCG with low-dose ritonavir boosting in combination with zidovudine and lamivudine in HIV-1 infected pregnant women: preliminary results of PACTG 386. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 887, 2003.

79. Connor SD et al. Risk of birth defects associated with nelfinavir exposure during pregnancy. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract P782, 2003.

80. McIntyre J et al. Evaluation of safety of two simple regimens for prevention of mother to child transmission (MTCT) of HIV infection 'Nevirapine (NVP) vs lamivudine (3TC)+zidovudine (ZDV)' used in a randomized clinical trial (The SAINT study). Thirteenth International Conference on AIDS, Durban, abstract TuOr356, 2000.

81. Thomas T et al. Preliminary findings: Incidence of serious adverse events attributed to nevirapine among women enrolled in an ongoing trial using HAART to prevent mother-to-child HIV transmission. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 809, 2005.

82. Timmermans S et al. Nelfinavir and nevirapine side-effects during pregnancy. AIDS 19: 795-799, 2005.

83. De Santis M et al. Periconceptional exposure to efavirenz and neural tube defects. Arch Intern Med 162: 355, 2002.

84. Fundaro C et al. Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 16: 299-300, 2002.

85. European Collaborative Study. Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr 40: 116-118, 2005.

86. Bucceri AM et al. Combination antiretroviral therapy in 100 HIV-1-infected pregnant women. Hum Reprod 17: 436-441, 2002.

87. Jungmann EM et al. Combination antiretroviral therapy in 100 HIV-1-infected pregnant women. Hum Reprod 17: 436-441, 2002.

88. Machado E et al. Pregnancy outcome in HIV-1-infected women receiving combination therapy prior to conception. Twelfth Conference on Retroviruses and Opportunistic Infections, abstract 808, 2005.

89. Kourtis AP et al. Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis. AIDS 21 (5): 607-615, 2007.

90. Tookey P et al. Antiretroviral therapy and pregnancy outcome: UK/Ireland surveillance data 1990-2004. Seventh International Congress on Drug Therapy in HIV Infection, Glasgow, abstract PL11.3, 2004.

91. Townsend Cl et al. Antiretroviral therapy and premature delivery in diagnosed HIV-infected women in the United Kingdom and Ireland. AIDS 21 (8): 1019-1026, 2007.

92. Thorne C et al. Increased risk of adverse pregnancy outcomes in HIV-infected women treated with highly active antiretroviral therapy in Europe. AIDS 18: 2337-2339, Year 2004.

93. Cotter AM et al. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight or stillbirth? J Infect Dis 193: 1195-1201, 2006.

94. Watts DH et al. Assessment of birth defects according to maternal therapy among infants in the Women and Infants Transmission Study. J Acquir Immune Defic Syndr 443: 299-305, 2007.

95. Goldstein P et al. Association between preterm birth and the use of protease inhibitors. Obstet Gynecol 93: S46, 1999.

96. Beckerman K et al. Association between antiretroviral therapy during pregnancy and prematurity/low birth weight. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 97, 2004.

97 Tuomala RE et al. Protease inhibitor use during pregnancy: is there an obstetrical risk? J Infect Dis 193: 1191-1194, 2006.

98 Morris AB et al. Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr 40: 30-33, 2005.

99. Toure H et al. Adverse pregnancy outcomes in HIV-infected women treated with HAART in Abidjan Côte d'Ivoire. Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, abstract TuFo0202, 2005.

100. Le Moing V et al. Pregnancy may be followed by an inflexion of the immune reconstitution in HIV-infected women who receive antiretroviral drugs before conception. HIV med 9(10): 897-900, 2008.

НАЧАЛО
ВТОРАЯ ЧАСТЬ

Считаете ли вы, что экстренная контрацепция должна предоставляться женщинам, пострадавшим от сексуального насилия, бесплатно?

© 2010 Российская Ассоциация "Народонаселение и Развитие" (РАНиР)
Лицензия № 77-01-001043 от 12.01.2006
Телефон: +7 (499) 973-14-37, факс: +7 (499) 978-79-85

Информируем, что 23 июня 2015 г. Минюст РФ внес Региональную общественную организацию содействия охране репродуктивного здоровья граждан «Народонаселение и развитие» в реестр НКО, в соответствии с Федеральным законом № 121-ФЗ от 20.07.2012.